Revance Therapeutics Inc

NASDAQ:RVNC  
27.82
+1.33 (+5.02%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.10B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$20.81 Million
Adjusted EPS-$0.97
See more estimates
10-Day MA$27.02
50-Day MA$28.22
200-Day MA$28.13
See more pivots

Revance Therapeutics Inc Stock, NASDAQ:RVNC

1222 Demonbreun Street, Suite 1001, Nashville, Tennessee 37203
United States of America
Phone: +1.615.724.7755
Number of Employees: 470

Description

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.